Global Managed Access Program Cohort for Ligelizumab in CSU

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Global Cohort Managed Access Program (MAP) to provide access to ligelizumab (QGE031) for chronic spontaneous urticaria (CSU)
Epistemonikos ID: 2941eeba32be8f8d61273a143db7162b3d8282ef
First added on: May 08, 2024